The Role of STAT5 in Tyrosine Kinase Inhibitor (IMATINIB) Resistance in CML Patients

QR Code

The Role of STAT5 in Tyrosine Kinase Inhibitor (IMATINIB) Resistance in CML Patients

Show other versions (1)

Chronic myeloid leukemia (CML) is a clonal haemopoietic stem cell disorders with reciprocal translocation in chromosome 9 (ch9) and 22 (ch22) which cause the fusion of Break cluster region-Abelson murine leukemia (BCR-ABL) oncogene. This fusion will activate tyrosine kinase. Imatinib mesylate is the...

Full description

Saved in:

Bibliographic Details
Main Authors:	Anastasia Putri, Ikhwan Rinaldi, Melva Louisa, Soekamto Koesnoe
Format:	Article
Language:	English
Published:	Interna Publishing 2020-02-01
Series:	Acta Medica Indonesiana
Subjects:	chronic Myeloid Leukemia STAT5 Imatinib tyrosine kinase inhibitor resistance
Online Access:	https://www.actamedindones.org/index.php/ijim/article/view/978
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

The Role of STAT5 in Tyrosine Kinase Inhibitor (IMATINIB) Resistance in CML Patients
by: Anastasia Putri, et al.
Published: (2020-02-01)

Chronic myeloid leukemia — before and after imatinib (Third part)
by: E. G. Lomaia, et al.
Published: (2022-11-01)

Tyrosine kinase inhibitors therapy related neutropenia and thrombocythopenia correction in CML patients
by: V. A. Shuvaev, et al.
Published: (2014-07-01)

The Mechanisms of Resistance to Tyrosine Kinase Inhibitor Imatinib Therapy of Chronic Myeloid Leukemia
by: S. I. Kutsev, et al.
Published: (2010-06-01)

Tyrosine Kinase Inhibitors for Gastrointestinal Stromal Tumor After Imatinib Resistance
by: Xian-Hao Xiao, et al.
Published: (2025-07-01)

ZFAS1/STAT3 axis modulates imatinib resistance of chronic myeloid leukemia cells through glucose metabolism reprogramming
by: Lan Yang, et al.
Published: (2025-07-01)

Cardiovascular and metabolic problems associated with application of second generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia
by: O. Y. Vinogradova
Published: (2015-10-01)

Dose Optimization of Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia
by: Chen J, et al.
Published: (2025-07-01)

Long-term treatment outcome in chronic myeloid leukemia patients in accelerated phase treated with imatinib (glevec®)
by: L. A. Antipova, et al.
Published: (2022-11-01)

COVID-19 Infection in Chronic Myeloid Leukemia Patients Receiving Tyrosine Kinase Inhibitor in Makassar, Indonesia: A Six-Case Report and Literature Review
by: Tutik Harjianti, et al.
Published: (2023-11-01)

Molecular genetics monitoring of tyrosine kinase inhibitor therapy for chronic myeloid leukemia
by: S. I. Kutsev, et al.
Published: (2022-11-01)

A Possible Association between Deep Molecular Response and Combination of Tyrosine Kinase Inhibitor and Immunochemotherapy in a Patient with Coexisting Chronic Myeloid Leukemia and Follicular Lymphoma: A Case Report
by: Wen-Yung Tsai, et al.
Published: (2025-04-01)

Mutation status of refractory to imatinib patients with chronic myeloid leukemia
by: E. G. Ovsyannikova, et al.
Published: (2014-07-01)

BCR-ABL gene amplification in patients with chronic myeloid leukemia and imatinib resistance
by: S. I. Kutzev, et al.
Published: (2022-11-01)

Long-Term Safety and Efficacy of Imatinib in Chronic Myeloid Leukemia: Real-World Evidence from a Single-Center Study
by: İsmail Can Kendir, et al.
Published: (2025-06-01)

REVERSAL OF ACCELERATED PHASE CML WITH HIGH BLAST COUNT FOLLOWING 5+2 CHEMOTHERAPY AND DASATINIB: A CASE REPORT
by: Büşra Akdoğan, et al.
Published: (2025-07-01)

Antitumor proteinkinase inhibitor imatinib may be regarded as a potential correcting agent for COVID-19 associated pulmonary fibrosis
by: I. N. Mikhaylova, et al.
Published: (2021-01-01)

Pharmacoeconomic analysis of treatment with nilotinib as the second line therapy in patients with chronic myeloid leukemia
by: N. A. Avxentyev, et al.
Published: (2018-08-01)

COST-EFFECTIVENESS ANALYSIS OVER USE OF TYROSINE KINASE INHIBITORS (TASIGNA AND GLEEVEC) FOR TREATMENT OF CHRONIC MYELOID LEUKEMIA IN THE CHRONIC PHASE AS FIRST-LINE THERAPY FOR DE NOVO PATIENTS
by: R. I. Yagudina, et al.
Published: (2015-03-01)

The Role of Plant-Derived Natural Products as a Regulator of the Tyrosine Kinase Pathway in the Management of Lung Cancer
by: Faris Alrumaihi, et al.
Published: (2025-06-01)

Chronic Myelogenous Leukemia Patients on Tyrosine Kinase Inhibitors—Hematological Changes and Correlation with European Leukemia Network Response Criteria
by: Karthik Bommannan, et al.

TOXICITY AND EFFICACY OF TYROSINE KINASE INHIBITORS IN COMBINATION WITH CHEMOTHERAPY IN PATIENT WITH RESISTANT Ph-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (CASE REPORT AND LITERATURE REVIEW)
by: K. I. Zarubina, et al.
Published: (2017-10-01)

COVID-19 infection in patients with chronic myeloid leukemia in the Orenburg region during the SARS-CoV-2 pandemic
by: G. B. Kuchma, et al.
Published: (2022-07-01)

Priapism as the first symptom of chronic myeloid leukemia: literature review and own clinical case report
by: T. Yu. Pavlova, et al.
Published: (2022-11-01)

Transformation of Chronic Myeloid Leukemia to Acute Undifferentiated Leukemia: Case Report and Literature Review
by: Oussama Grari, et al.
Published: (2025-04-01)

Efficacy of Bosutinib therapy as a second line in the treatment of chronic myeloid leukemia: A single-center study
by: Alaa Fadhil Alwan, et al.
Published: (2025-01-01)

Pharmacoeconomic modeling of target therapy of chronic myeloid leukemia in remission
by: V. A. Shuvaev, et al.
Published: (2015-01-01)

Eligibility for treatment-free remission among chronic myeloid leukemia patients in Iraqi Kurdistan region
by: Haydar Hasan Darwes, et al.
Published: (2025-01-01)

Metabolomic Profiling and Bioanalysis of Chronic Myeloid Leukemia: Identifying Biomarkers for Treatment Response and Disease Monitoring
by: Selim Sayın, et al.
Published: (2025-06-01)

Establishment of in vitro Src tyrosine kinase inhibitors screening model
by: WANG Chen-hui, et al.
Published: (2007-11-01)

Treatment efficacy of chronic myeloid leukemia with imatinib in clinical practice
by: A. K. Golenkov, et al.
Published: (2014-07-01)

Immunomodulating effects of antitumor drugs Bruton tyrosine kinase inhibitors and the possibility of their use in allergic and infectious diseases
by: Yu. S. Torshina, et al.
Published: (2023-06-01)

Cost impact of Bruton’s tyrosine kinase inhibitor selection in Medicare patients with chronic lymphocytic leukemia
by: Adam S Kittai, et al.
Published: (2025-01-01)

CLINICAL CASE OF TREATMENT OF A PATIENT WITH CHRONIC MYELOID LEUKEMIA WITH A MUTATION BCR-ABL Y253H AND COMORBIDITIES
by: G. Sh. Safuanova, et al.
Published: (2019-05-01)

Treatment-free remission in patients with chronic myeloid leukemia: literature review
by: A. N. Petrova, et al.
Published: (2019-10-01)

Evolution of therapeutic approaches in patients with chronic myeloid leukemia and T315I mutation
by: A. G. Turkina, et al.
Published: (2024-12-01)

Immunomodulatory role of spleen tyrosine kinase in chronic inflammatory and autoimmune diseases
by: Yaqi Zhou, et al.
Published: (2023-07-01)

Atypical Cystic Primary Hepatic GIST: A Case Report of Rare Presentation and Long-Term Survival
by: Mirela Claudia Rimbu, et al.
Published: (2025-07-01)

Efficacy and safety of tyrosine kinase inhibitors (dasatinib, nilotinib) in the treatment of chronic phase chronic myeloid leukemia
by: E. G. Lomaia, et al.
Published: (2014-07-01)

Cytokine profile in patients with chronic myeloid leukemia
by: T. N. Aleksandrova, et al.
Published: (2024-01-01)